Quest Diagnostics (DGX) Tops Q2 EPS by 210c

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $4.96, $2.10 better than the analyst estimate of $2.86. Revenue for the quarter came in at $2.55 billion versus the consensus estimate of $2.38 billion.

GUIDANCE:

Quest Diagnostics sees FY2021 EPS of $10.65-$11.35, versus the consensus of $11.13. Quest Diagnostics sees FY2021 revenue of $9.54-9.79 billion, versus the consensus of $9.45 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
• Starlink, AI Capex, rockets: deep dive into SpaceX’s first ever public report
• Sportradar Group AG (SRAD) Misses Q2 EPS by 6c, Offers Guidance